Part D Premium Protection Act of 2026
- Sponsor
- Rep. Bilirakis, Gus M. [R-FL-12]
- Committees
- Ways and Means Committee (primary)
- Last action
- Aug 31, 2026
Bottom line
The bill aims to temporarily lower Medicare Part D prescription drug premiums for beneficiaries in 2027 by having the federal government cover a portion of their costs, based on a prior demonstration program.
What it actually does
This bill, the "Part D Premium Protection Act of 2026," mandates the Secretary of Health and Human Services to create a temporary premium credit for Medicare Part D prescription drug plan enrollees for the year 2027. The credit amount will be equivalent to the average premium reduction observed in the Part D Premium Stabilization Demonstration from 2025-2026. This credit will directly reduce the monthly premiums paid by beneficiaries, with the federal government reimbursing the drug plan sponsors for the credited amount.
Proponents argue
Supporters argue that this bill provides crucial financial relief to Medicare beneficiaries facing rising prescription drug costs, making essential medications more affordable. They contend that by leveraging the success of a previous demonstration program, it offers a proven method to stabilize premiums and reduce out-of-pocket expenses for seniors, ensuring access to necessary healthcare without undue financial burden.
Opponents contend
Critics may argue that while seemingly beneficial, this bill represents a temporary and unfunded federal expenditure that will increase the national deficit without addressing the root causes of high drug costs. They might also contend that it interferes with market mechanisms for premium setting and could create an expectation for ongoing federal subsidies, potentially leading to future fiscal challenges.
The bill is very short and can be read in under two minutes, allowing ample time for an informed reader to understand its provisions.
Section 2(a) and (b)
Establishment of Temporary Medicare Part D Premium Credit for 2027
This section requires the Secretary of Health and Human Services to create a premium credit for all enrollees in Medicare Part D prescription drug plans for the calendar year 2027. The value of this credit will be determined by the average premium reduction achieved in a specific 'Part D Premium Stabilization Demonstration' that ran from 2025 through 2026. Drug plan sponsors will subtract this credit from enrollees' monthly premiums, ensuring the premium doesn't go below zero, and the federal government will then reimburse the sponsors for the credited amount.
Supporters argue
Proponents argue this provision directly addresses the affordability crisis in prescription drugs by providing immediate, tangible relief to seniors. They highlight that basing the credit on a successful demonstration program ensures a data-driven and effective reduction in out-of-pocket costs, improving access to necessary medications.
Critics contend
Opponents may argue that while beneficial to enrollees, this provision shifts the financial burden from individuals to taxpayers, increasing federal spending without addressing the underlying cost drivers of prescription drugs. They might also raise concerns about the administrative complexity for plan sponsors and the potential for creating an expectation of continued subsidies.
Tradeoffs
The provision balances the immediate need for beneficiary financial relief against the long-term fiscal implications for the federal budget. It also involves a tension between direct government intervention in premium setting and market-based approaches to healthcare costs.
The bill defines the premium credit amount by referencing the 'average premium reduction applicable with respect to enrollees in participating PDPs under the Part D Premium Stabilization Demonstration (as described in the announcement issued by the Centers for Medicare & Medicaid Services on July 29, 2024) conducted pursuant to section 402 of the Social Security Amendments of 1967 (42 U.S.C. 1395b-1)'.
Section 2(a)
Why it matters:This is standard legislative practice to reference existing programs or data for calculation, rather than embedding dynamic figures directly into statute. However, it means the bill's full financial implications are not immediately apparent from its text alone.
Case for: Referencing an existing demonstration allows for a data-driven approach, ensuring the credit is based on observed premium reductions, and avoids the need for Congress to set an arbitrary figure.
Case against: Without the specific details of the referenced demonstration and its outcomes, the actual financial benefit to enrollees and the cost to the federal government remain opaque to a reader of the bill, making it difficult to fully assess its impact.
Estimated impact: The total impact is unknown without the specific data from the referenced demonstration, but it will represent a significant federal expenditure to offset Part D premiums for all enrollees for one year.